You are here:- Finalised Projects .. Guidance: HIV Indicator Conditions

Guidance: HIV in Indicator Conditions

The objectives of the guidance are to:
• Encourage and support the inclusion of indicator condition-guided HIV testing in national HIV testing strategies, taking into account the local HIV prevalence, ongoing testing programmes and the local healthcare setting;
• Recommend approaches and practical tools for education and training of healthcare professionals on overcoming barriers to recommending an HIV test.

HIV indicator conditions can be divided into 3 categories:
1. Conditions which are AIDS defining among PLHIV;
2. Conditions associated with an undiagnosed HIV prevalence of >0.1%;
3. Conditions where not identifying the presence of HIV infection may have significant adverse implications for the individual’s clinical management.

There is a large body of  evidence from randomised controlled trials on the consequences of not treating people living with HIV who have AIDS defining conditions. Not recommending a test in these circumstances would not be considered good clinical practice. Routine testing for conditions with an HIV prevalence of >0.1% has been reported to be cost-effective and has the potential to increase earlier diagnosis of HIV, and thus lead to earlier opportunities for care and treatment.

Recommendations:
• Any person (without an HIV-positive test in the patient’s medical record) presenting with potentially AIDS defining conditions should be strongly recommended HIV testing.
• Any person presenting with a condition with an undiagnosed HIV prevalence of >0.1% should be strongly recommended HIV testing. 
• For indicator conditions where expert opinion considers HIV prevalence likely to be >0.1%, but awaiting further evidence, it is recommended to offer testing.
• For conditions where not identifying the presence of HIV infection may have significant adverse implications for the individual’s clinical management, testing should be offered to avoid further immune suppression with potentially serious adverse outcomes for the individual, and to maximize the potential response to the treatment of the indicator condition (despite that the estimated prevalence of HIV is most likely lower than 0.1%).   

Guidance document: HIV Indicator Conditions: Guidance for Implementing HIV Testing in Adults in Health Care Settings (update coming soon)

Please find below an executive summary/ short version of the Guidance document translated into other languages. If you find any mistakes in the translation for your language, please contact the HIV in Europe Secretariat hie.rigshospitalet@regionh.dk

Guidance in short - English

Guidance in short - Albanian

Guidance in short - Arabic

Guidance in short - Bosnian

Guidance in short - Bulgarian

Guidance in short - Croatian

Guidance in short - Czech

Guidance in short - Danish

Guidance in short - Estonian

Guidance in short - Finnish

Guidance in short - French

Guidance in short - German 

Guidance in short - Greek

Guidance in short - Hebrew

Guidance in short - Hungarian

Guidance in short - Icelandic

Guidance in short - Italian

Guidance in short - Lithuanian

Guidance in short -Macedonian

Guidance in short - Maltese

Guidance in short - Norwegian

Guidance in short - Polish

Guidance in short - Romanian

Guidance in short - Russian

Guidance in short - Serbian

Guidance in short - Spanish

Guidance in short - Slovak

Guidance in short - Slovenian

Guidance in short - Swedish

Guidance in short - Turkish

Pdf-version (coming soon)

Appendix 4: Example of patient information leaflet (coming soon)

Appendix 5: Example of presentation of guidance (coming soon)

Appendix 6: Template letter to the editor (coming soon)

NEWS
 Late presentation of chronic viral hepatitis for medical care: a consensus definition
Monday, May 08, 2017

New publication! Late presentation of chronic viral hepatitis for medical care: a consensus definition. Read the full article here.

 
 Two-day short course on Introduction to Cost-effectiveness Analysis for Infectious Diseases at UCL
Tuesday, April 04, 2017

Don't miss out! Join a two-day short course on Introduction to Cost-effectiveness Analysis for Infectious Diseases at UCL. The course takes place on 28 and 29 September 2017. Read more here.

 
 Evaluation of the HepHIV 2017 Conference
Monday, April 03, 2017

The evaluation report from the HepHIV conference is now available. You can access it here.

 
 The HIV in Europe 2016 Annual Report is now available!
Monday, April 03, 2017

You can now read about our 2016 projects, activities and achievements in our annual report. Find it here.

 
 New report: The HIV in Europe initiative - the first 10 years
Tuesday, January 31, 2017

2017 marks 10 years of HIV in Europe - read about the 10 years of working with different stakeholders to promote earlier testing and care in our new report

 
 HepHIV 2017 Malta Conference
Tuesday, January 31, 2017

HepHIV 2017 Conference is now taking place in Malta (31 January - 2 February 2017). See full programme here. You can also follow news and updates on Twitter by following the conference hashtag #HepHIV2017

 

Copyright 2009 by HIV in Europe